Replimune Group Ownership | Who Owns Replimune Group?


OverviewForecastRevenueFinancialsChart

Replimune Group Ownership Summary


Replimune Group is owned by 25.84% institutional investors, 4.18% insiders, and 69.98% retail investors. Baker bros. advisors lp is the largest institutional shareholder, holding 14.06% of REPL shares. US Small-Cap Growth II Equity Comp is the top mutual fund, with 6.15% of its assets in Replimune Group shares.

REPL Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockReplimune Group25.84%4.18%69.98%
SectorHealthcare Stocks 57.38%9.40%33.23%
IndustryBiotech Stocks 68.91%8.92%22.17%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Baker bros. advisors lp11.05M14.06%$133.76M
Price t rowe associates inc /md/10.96M13.95%$132.76M
Fcpm iii services b.v.4.87M7.31%$43.80M
Blackrock funding, inc. /de5.57M7.08%$67.41M
Blackrock4.71M7.08%$42.42M
Redmile group4.91M6.24%$59.41M
Vanguard group3.60M4.58%$43.55M
Sofinnova investments3.15M4.01%$38.14M
Omega fund management2.46M3.70%$22.15M
Tang capital management2.70M3.44%$32.70M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Omega fund management2.46M16.41%$22.15M
Fcpm iii services b.v.4.87M6.46%$43.80M
Redmile group4.91M4.14%$59.41M
Nan fung group321.75K3.33%$3.90M
Sofinnova investments3.15M2.78%$38.14M
Tang capital management2.70M2.16%$32.70M
Velan capital investment management lp181.37K1.90%$2.20M
Bioimpact capital950.00K1.63%$11.50M
Rosalind advisors260.00K1.61%$3.15M
Baker bros. advisors lp11.05M1.43%$133.76M

Top Buyers

HolderShares% AssetsChange
Sofinnova investments3.15M2.78%3.10M
Boxer capital1.54M0.73%1.54M
Tang capital management2.70M2.16%1.50M
Rtw investments, lp1.13M0.16%1.13M
Price t rowe associates inc /md/10.96M0.02%1.08M

Top Sellers

HolderShares% AssetsChange
State street1.16M0.00%-5.33M
Atlas venture life science advisors---2.10M
Braidwell lp1.48M0.53%-1.59M
Camber capital management lp---1.35M
Jefferies financial group---1.00M

New Positions

HolderShares% AssetsChangeValue
Boxer capital1.54M0.73%1.54M$13.83M
Rtw investments, lp1.13M0.16%1.13M$10.20M
Bioimpact capital950.00K1.63%950.00K$11.50M
Marshall wace, llp896.18K0.01%896.18K$10.85M
Artisan partners limited partnership611.01K0.01%611.01K$7.40M

Sold Out

HolderChange
Nelson, van denburg & campbell wealth management group-8.00
Global retirement partners-32.00
Riggs asset managment-58.00
Capital performance advisors llp-76.00
Truvestments capital-80.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Dec 31, 202491-38.10%20,304,371-70.81%250.33%55-30.38%17-56.41%
Sep 30, 2024147-2.65%69,570,682-1.86%880.84%80-8.05%39-17.02%
Jun 30, 2024150-2.60%70,892,1786.49%1061.07%863.61%4720.51%
Mar 31, 20241544.76%66,572,5110.83%991.02%83-10.75%3921.88%
Dec 31, 20231470.68%66,021,20516.25%991.35%9338.81%32-21.95%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
US Small-Cap Growth II Equity Comp4.73M6.15%337.32K
T. Rowe Price New Horizons4.73M6.15%-
T. Rowe Price Integrated US SmCapGrEq2.96M3.85%1.63M
Vanguard Total Stock Mkt Idx Inv1.99M2.58%-
T. Rowe Price Health Sciences1.72M2.23%-4.53K
iShares Russell 2000 ETF1.60M2.07%-31.24K
T. Rowe Price Integrated US Sm Gr Eq1.48M1.93%-
T. Rowe Price New Horizons Tr-Z1.28M1.66%274.81K
Vanguard Institutional Extnd Mkt Idx Tr888.40K1.15%281.00
SPDR® S&P Biotech ETF825.98K1.07%6.26K

Recent Insider Transactions


DateNameRoleActivityValue
Dec 16, 2024Patel Sushil Chief Executive OfficerSell$124.20K
Nov 18, 2024Xynos Konstantinos Chief Medical OfficerSell$78.11K
Nov 18, 2024Sarchi Christopher Chief Commercial OfficerSell$56.13K
Aug 16, 2024Hill Emily Luisa Chief Financial OfficerSell$90.99K
Jun 07, 2024Xynos Konstantinos Chief Medical OfficerSell$119.11K

Insider Transactions Trends


DateBuySell
2025 Q1--
2024 Q4-3
2024 Q3-1
2024 Q2-8
2023 Q4-2

REPL Ownership FAQ


Who Owns Replimune Group?

Replimune Group shareholders are primarily institutional investors at 25.84%, followed by 4.18% insiders and 69.98% retail investors. The average institutional ownership in Replimune Group's industry, Biotech Stocks , is 68.91%, which Replimune Group falls below.

Who owns the most shares of Replimune Group?

Replimune Group’s largest shareholders are Baker bros. advisors lp (11.05M shares, 14.06%), Price t rowe associates inc /md/ (10.96M shares, 13.95%), and Fcpm iii services b.v. (4.87M shares, 7.31%). Together, they hold 35.32% of Replimune Group’s total shares outstanding.

Does Blackrock own Replimune Group?

Yes, BlackRock owns 7.08% of Replimune Group, totaling 4.71M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 42.42M$. In the last quarter, BlackRock increased its holdings by 101.23K shares, a 2.19% change.

Who is Replimune Group’s biggest shareholder by percentage of total assets invested?

Omega fund management is Replimune Group’s biggest shareholder by percentage of total assets invested, with 16.41% of its assets in 2.46M Replimune Group shares, valued at 22.15M$.

Who is the top mutual fund holder of Replimune Group shares?

US Small-Cap Growth II Equity Comp is the top mutual fund holder of Replimune Group shares, with 6.15% of its total shares outstanding invested in 4.73M Replimune Group shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools